Co-Diagnostics

Co-Diagnostics, Inc. engages in the development and innovation of molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. Its diagnostics systems enable very rapid, low-cost, molecular testing for organisms and genetic diseases by automating historically complex procedures in both the development and administration of tests. The company was founded by Brent C. Satterfield and Dwight Howard Egan on April 18, 2013 and is headquartered in Salt Lake City, UT.

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Earnings data Q4 2025

Earnings data Q1 2026

Co-Diagnostics reports Q1 results, focuses on growth and innovation

Co-Diagnostics reported mixed financial results for Q1 2024, with revenue decrease but gross profit increase.
The company is strategically focused on commercialization efforts, product development, and managing expenses for growth.
Despite facing challenges such as net losses and operational complexities, Co-Diagnostics remains optimistic about future opportunities.
With a strong cash position and ongoing FDA submissions, Co-Diagnostics is poised for potential revenue growth and market expansion.

Co-Diagnostics reports Q3 revenue decline, focuses on global expansion

Co-Diagnostics faces financial challenges with a significant net loss in Q3 2024 but maintains a strong focus on advancing its testing platforms and expanding manufacturing capabilities.
Strategic opportunities in international market expansion and test development supported by grants present avenues for growth and market penetration.
Efforts to manage cash position through efficient spending and operational efficiencies underscore the company's commitment to future commercial success.

Co-Diagnostics addresses regulatory challenges, focuses on growth opportunities post-Q4

Co-Diagnostics navigated challenges in 2024, focusing on regulatory compliance, operational enhancements, and financial management for future growth. Despite legal and financial hurdles, the company's commitment to innovation, clinical evaluations, and manufacturing expansion positions them for success. With a strategic approach to addressing regulatory feedback, managing expenses, and seeking growth opportunities, Co-Diagnostics aims for sustainable profitability.

Co-Diagnostics reports revenue decline but optimistic on diagnostic advancements

Co-Diagnostics faced a decline in revenue and incurred a net loss in Q1 2025. However, the company is strategically focused on advancing its diagnostic solutions and maintaining financial stability. Opportunities lie in upcoming clinical evaluations and the potential for successful commercialization. Challenges include the need to address revenue decline and ensure successful clinical evaluations.

Co-Diagnostics reports Q2 revenue decline but advances clinical test plans

Co-Diagnostics demonstrated financial resilience with reduced operating expenses despite a decline in revenue, maintaining a solid cash position. Progress in clinical evaluations and plans for FDA submissions indicate a strategic focus on product development and market entry for diagnostic tests. Challenges lie in revenue generation, timely commercialization, and managing financial resources amidst ambitious growth plans and regulatory requirements.

Co-Diagnostics reports Q3 results, eyes growth through strategic initiatives

Co-Diagnostics' Q3 2025 performance showed modest revenue, a net loss, and a focus on strategic growth pillars. The company is addressing challenges through cost control measures and strategic initiatives. Opportunities for growth include potential transactions, clinical evaluations, and operational optimization.

Co-Diagnostics reports Q4 2025 earnings, patents secured, challenges ahead

Co-Diagnostics showcased progress in key growth areas and secured patents in Australia and Japan, bolstering their market position. While facing challenges of significant operating expenses and strategic decisions, the company maintains a focus on disciplined capital allocation and innovation. Opportunities lie in market expansion in South Asia, regulatory advancements with the FDA, and potential growth through strategic alternatives like SPAC transactions.